Slide 1: Fourth Quarter & Year-End 2016 Results
K Pharm Fourth Quarter & Year-End 2016 Results
Slide 2: Cautionary Note Regarding Presentation Information
Cautionary Note Regarding Presentation Information This presentation contains forward-looking statements, including statements about our plans to develop and commercialize our product candidates, our planned clinical trials for our prodrug product candidates, the timing of and our ability to obtain
Slide 3: Fourth Quarter & Year-End 2016 — Conference Call Participants
Fourth Quarter & Year-End 2016 — Conference Call Participants ¢ Travis Mickle, Ph.D. — President & Chief Executive Officer + R. LaDuane Clifton — Chief Financial Officer
Slide 4: KemPharm Overview
KemPharm Overview + Specialty pharmaceutical company discovering and developing novel prodrugs « Leveraging our LAT Platform Technology to improve the attributes of approved drugsin large markets + Building a pipeline of product candidates for the treatment of ADHD, pain and CNS disorders + Potentia
Slide 5: Ligand Activated Therapy (LAT) Platform Technology
Ligand Activated Therapy (LAT) Platform Technology ax ©” aD ax © ( ( —_ —— Approved Drug with Ligand Prodrugwith Cleaved Drug through Sub-Optimal Improved Attributes Human Metabolic Properties Process 1) Select FDA-approved and widely prescribed drug for improvement 2) Chemically modify using a liga
Slide 6: Q4/YE 2016 & Recent Updates
Q4/YE 2016 & Recent Updates Clinical & Regulatory Financial + Reported Positive Data from Phase 1 + Net loss of $0.68 per basic and diluted Proof-of-Concept Clinical Trial of KP415 share for the quarter ended 12/31/2016 + Received Clearance from FDA to + Total cash was $82.1 million at Initiate Clin
Slide 7: KP415 Product Overview
KP415 Product Overview Extended release prodrug of methylphenidate Phase 1 PoC Data: Earlier d- MPH exposure followed by a slower extended release of d-MPH relative to Concerta Data from preclinical studies suggests KP415 could allow for once-daily dosing with a potentially improved onset of action
Slide 8: KP201/IR (APAP-free)
KP201/IR (APAP-free) Product Overview Development Timeline + IR formulation of benzhydrocodone v KP201/IR IND accepted by FDA on combined with an aversive formulation Potentially the first IR hydrocodone- related product without APAP in the U.S. Fast Track designation KP201 Intranasal PK Trial (A03)
Slide 9: KP511/ER and KP511/IR
KP511/ER and KP511/IR Product Overview + Prodrug of hydromorphone + Being developed as ER and IR formulations + Demonstrated comparable hydromorphone exposure vs. equimolar dose of Dilaudid™ in oral human proof-of-concept trial + Phase 1 Intranasal Data: Demonstrated statistically significant PK and
Slide 10: Q4/ YE 2016 Financial Update
Q4/ YE 2016 Financial Update * Q4 2016 net loss of $10.0M, or $0.68 per basic and diluted share, vs. Q4 2015 net loss of $9.2M, or $0.64 per basic and diluted share Increased net loss for Q4 2016 driven primarily by the $3,5M payment to license the Aversion™ technology, increased activity on the dev
Slide 11: KemPharm Expected Milestones
KemPharm Expected Milestones Product KP415 KP415 2017 KP415 KP201/IR KP201/IR KP415 2018 KP415 KP201/IR 2019 | KP511/ER & KP511/IR Eve Initiate Additional PK Studies (1H) Report Additional PK Data (2H) Initiate Pivotal Efficacy Trial (2H) Human Clinical Trial Initiation (Mid) Intranasal HAL Study Da
Slide 12: Fourth Quarter & Year-End 2016 Results
K Pharm Fourth Quarter & Year-End 2016 Results